Journal of Hepatology
Volume 49, Issue 4 , Pages 581-588 , October 2008

Liver transplantation for hepatocellular carcinoma: Extension of indications based on molecular markers

  • Myron Schwartz

      Affiliations

    • Mount Sinai Liver Cancer Program, [Department of Surgery, Recanati Miller Transplantation Institute, Division of Liver Disease, Department of Pathology], 1 Gustave Levy Place, New York, NY 10029, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 212 241 2891; fax: +1 212 241 1572.
    • ,
  • Igor Dvorchik

      Affiliations

    • Department of Surgery, University of Pittsburgh, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA
    • ,
  • Sasan Roayaie

      Affiliations

    • Mount Sinai Liver Cancer Program, [Department of Surgery, Recanati Miller Transplantation Institute, Division of Liver Disease, Department of Pathology], 1 Gustave Levy Place, New York, NY 10029, USA
    • ,
  • M. Isabel Fiel

      Affiliations

    • Mount Sinai Liver Cancer Program, [Department of Surgery, Recanati Miller Transplantation Institute, Division of Liver Disease, Department of Pathology], 1 Gustave Levy Place, New York, NY 10029, USA
    • ,
  • Sidney Finkelstein

      Affiliations

    • Department of Surgery, University of Pittsburgh, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA
    • ,
  • J. Wallis Marsh

      Affiliations

    • Department of Surgery, University of Pittsburgh, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA
    • ,
  • John A. Martignetti

      Affiliations

    • Departments of Human Genetics, Pediatrics and Oncological Sciences, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York, NY 10029, USA
    • ,
  • Josep M. Llovet

      Affiliations

    • Mount Sinai Liver Cancer Program, [Department of Surgery, Recanati Miller Transplantation Institute, Division of Liver Disease, Department of Pathology], 1 Gustave Levy Place, New York, NY 10029, USA
    • BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, Barcelona, Spain

Received 18 November 2007 ,Revised 22 March 2008 ,Accepted 25 March 2008.

References 

  1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699
  3. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127:S268–S276
  4. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200
  5. Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg. 2002;235:533–539
  6. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the milan criteria and the pittsburgh modified TNM criteria. Liver Transpl. 2002;8:765–774
  7. Llovet JM, Wurmbach E. Gene expression profiles in hepatocellular carcinoma: not yet there. J Hepatol. 2004;41:336–339
  8. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40:667–676
  9. Iizuka N, Hamamoto Y, Oka M. Predicting individual outcomes in hepatocellular carcinoma. Lancet. 2004;364:1837–1839
  10. Kurokawa Y, Matoba R, Takemasa I, Nagano H, Dono K, Nakamori S, et al. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol. 2004;41:284–291
  11. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–799
  12. Marsh JW, Finkelstein SD, Demetris AJ, Swalsky PA, Sasatomi E, Bandos A, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl. 2003;9:664–671
  13. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236
  14. Finkelstein SD, Marsh W, Demetris AJ, Swalsky PA, Sasatomi E, Bonham A, et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology. 2003;37:871–879
  15. Kirimlioglu H, Dvorchick I, Ruppert K, Finkelstein S, Marsh JW, Iwatsuki S, et al. Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: biologic and therapeutic implications. Hepatology. 2001;34:502–510
  16. Dacic S, Ionescu DN, Finkelstein S, Yousem SA. Patterns of allelic loss of synchronous adenocarcinomas of the lung. Am J Surg Pathol. 2005;29:897–902
  17. Krishnamurti U, Sasatomi E, Swalsky PA, Jones MW, Finkelstein SD. Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int J Gynecol Pathol. 2005;24:56–61
  18. Rao UN, Goodman M, Chung WW, Swalski P, Pal R, Finkelstein S. Molecular analysis of primary and recurrent giant cell tumors of bone. Cancer Genet Cytogenet. 2005;158:126–136
  19. Beckner ME, Sasatomi E, Swalsky PA, Hamilton RL, Pollack IF, Finkelstein SD. Loss of heterozygosity reveals non-VHL allelic loss in hemangioblastomas at 22q13. Hum Pathol. 2004;35:1105–1111
  20. Hunt JL, Fowler M, Lomago D, Niehouse L, Sasatomi E, Swalsky P, et al. Tumor suppressor gene allelic loss profiles of the variants of papillary thyroid carcinoma. Diagn Mol Pathol. 2004;13:41–46
  21. Khalid A, Pal R, Sasatomi E, Swalsky P, Slivka A, Whitcomb D, et al. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut. 2004;53:1860–1865
  22. Lee JY, Finkelstein S, Hamilton RL, Rekha R, King JT, Omalu B. Loss of heterozygosity analysis of benign, atypical, and anaplastic meningiomas. Neurosurgery. 2004;55:1163–1173
  23. Ariyanayagam-Baksh SM, Baksh FK, Swalsky PA, Finkelstein SD. Loss of heterozygosity in the MXI1 gene is a frequent occurrence in melanoma. Mod Pathol. 2003;16:992–995
  24. Dacic S, Finkelstein SD, Baksh FK, Swalsky PA, Barnes LE, Yousem SA. Small-cell neuroendocrine carcinoma displays unique profiles of tumor-suppressor gene loss in relationship to the primary site of formation. Hum Pathol. 2002;33:927–932
  25. Raja S, Finkelstein SD, Baksh FK, Gooding WE, Swalsky PA, Godfrey TE, et al. Correlation between dysplasia and mutations of six tumor suppressor genes in barrett’s esophagus. Ann Thorac Surg. 2001;72:1130–1135
  26. Iacobuzio-Donahue CA, van der Heijden MS, Baumgartner MR, Troup WJ, Romm JM, Doheny K, et al. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res. 2004;64:871–875
  27. Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg. 2007;245:435–442
  28. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg. 2004;239:150–159
  29. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003;38:1034–1042
  30. Ravaioli M, Ercolani G, Cescon M, Vetrone G, Voci C, Grigioni WF, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl. 2004;10:1195–1202

☆ NIH funded study (Grant K24 DK 60498-01). The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(08)00295-X

doi: 10.1016/j.jhep.2008.03.032

Journal of Hepatology
Volume 49, Issue 4 , Pages 581-588 , October 2008

Article Tools

* Image Usage & Resolution